EcoDrugPlus

Kras Proto-Oncogene, Gtpase

Ensembl ID : ENSMMSG00000023808
Gene Symbol: KRAS
1 Cross references
201 Possible Orthologues:

Lck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSMMSG00000013485
Gene Symbol: LCK
1 Cross references
120 Possible Orthologues:

Lyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSMMSG00000018689
Gene Symbol: LYN
1 Cross references
202 Possible Orthologues:

Malt1 Paracaspase

Ensembl ID : ENSMMSG00000002981
Gene Symbol: MALT1
1 Cross references
195 Possible Orthologues:

Mapk Activated Protein Kinase 2

Ensembl ID : ENSMMSG00000005784
Gene Symbol: MAPKAPK2
1 Cross references
233 Possible Orthologues:

Mapk Activated Protein Kinase 5

Ensembl ID : ENSMMSG00000016553
Gene Symbol: MAPKAPK5
1 Cross references
179 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 1

Ensembl ID : ENSMMSG00000019302
Gene Symbol: MKNK1
1 Cross references
167 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 2

Ensembl ID : ENSMMSG00000001783
Gene Symbol: MKNK2
1 Cross references
220 Possible Orthologues:

Mcl1 Apoptosis Regulator, Bcl2 Family Member

Ensembl ID : ENSMMSG00000019746
Gene Symbol: MCL1
1 Cross references
239 Possible Orthologues:

Mdm2 Proto-Oncogene

Ensembl ID : ENSMMSG00000019866
Gene Symbol: MDM2
1 Cross references
182 Possible Orthologues:

Met Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSMMSG00000010268
Gene Symbol: MET
1 Cross references
211 Possible Orthologues:

Mpl Proto-Oncogene, Thrombopoietin Receptor

Ensembl ID : ENSMMSG00000010790
Gene Symbol: MPL
1 Cross references
186 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).